Science Explorer Back to mapMap
Discussion
Institution · Orlando Clinical Research Center

Most cited papers from Orlando Clinical Research Center

Orlando Clinical Research Center

What are the most cited papers from Orlando Clinical Research Center?

The most cited paper from Orlando Clinical Research Center is "Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients" (Robert Gottlieb et al., 2021), with 1,288 citations. Next come "All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study" (694) and "Anaritide in Acute Tubular Necrosis" (443).

Showing 50 of 60 papers. Every paper with more than 46 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients Robert Gottlieb et al. · New England Journal of Medicine Open access 22 Dec 2021 1,288
2 All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study David R. Nelson et al. · Hepatology Open access 23 Jan 2015 694
3 Anaritide in Acute Tubular Necrosis Robin L. Allgren, Thomas C Marbury, Sahinur Rahman et al. · New England Journal of Medicine Open access 20 Mar 1997 443
4 Pressure Sores Classification and Management J. DARRELL SHEA · Clinical Orthopaedics and Related Research Oct 1975 378
5 Disparities in Physical Activity and Sedentary Behaviors Among US Children and Adolescents: Prevalence, Correlates, and Intervention Implications Melicia C. Whitt‐Glover, Wendell C. Taylor, Myron F. Floyd et al. · Journal of Public Health Policy 2009 330
6 Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis Xiaoli Wang, Giridhar Tirucherai, Thomas C Marbury et al. · The Journal of Clinical Pharmacology Open access 2 Sep 2015 289
7 Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension Suzanne Oparil, David Williams, Steven G. Chrysant et al. · Journal of Clinical Hypertension Open access Sep 2001 265
8 Atrial natriuretic factor in oliguric acute renal failure Julia Breyer Lewis, Mahmoud Salem, Glenn Matthew Chertow et al. · American Journal of Kidney Diseases Oct 2000 253
9 Clinical improvement in psoriasis with specific targeting of interleukin-23 Tamara Kopp, Elisabeth Riedl, Christine Bangert et al. · Nature 6 Mar 2015 209
10 Effect of Renal Insufficiency on the Pharmacokinetics of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor Arthur J. Bergman, Josée Côté, Bingming Yi et al. · Diabetes Care Open access 27 Jun 2007 197
11 Repaglinide versus glyburide: a one-year comparison trial Thomas C Marbury, Won‐Chin Huang, Poul Strange et al. · Diabetes Research and Clinical Practice Mar 1999 187
12 Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial Eric S. Daar, Edwin DeJesus, Peter Jerome Ruane et al. · The Lancet HIV 18 Jun 2018 182
13 Pharmacokinetics of Micafungin in Healthy Volunteers, Volunteers With Moderate Liver Disease, and Volunteers With Renal Dysfunction Mary F. Hébert, Helen Elizabeth Smith, Thomas C Marbury et al. · The Journal of Clinical Pharmacology 19 Sep 2005 180
14 Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 Richard E. Nettles, Min Gao, Marc Bifano et al. · Hepatology Open access Dec 2010 177
15 Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir Larissa A. Wenning, William D. Hanley, Diana M. Brainard et al. · Antimicrobial Agents and Chemotherapy Open access 12 May 2009 161
16 A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C Eric Lawitz, Daniel Gruener, John M. Hill et al. · Journal of Hepatology 5 Feb 2012 158
17 Acyclovir Cream for Treatment of Herpes Simplex Labialis: Results of Two Randomized, Double-Blind, Vehicle-Controlled, Multicenter Clinical Trials Spotswood L. Spruance, Robert Nett, Thomas C Marbury et al. · Antimicrobial Agents and Chemotherapy Open access Jul 2002 149
18 Safety and Immunogenicity of a Bivalent Cytomegalovirus DNA Vaccine in Healthy Adult Subjects Mary Kopke Wloch, Larry R Smith, Souphaphone Boutsaboualoy et al. · The Journal of Infectious Diseases Open access 29 Apr 2008 140
19 Randomized Controlled Trial Comparing All‐Inside Anterior Cruciate Ligament Reconstruction Technique With Anterior Cruciate Ligament Reconstruction With a Full Tibial Tunnel James H. Lubowitz, Randy Schwartzberg, Patrick A. Smith · Arthroscopy The Journal of Arthroscopic and Related Surgery 26 Jun 2013 134
20 Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis Thomas C Marbury, Nobuko Matsushima, Shuquan Chen et al. · Thrombosis and Haemostasis 8 Jan 2015 132
21 Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease Ronan Courtney, Angela Sansone, Winter J. Smith et al. · The Journal of Clinical Pharmacology 12 Jan 2005 130
22 Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment Thomas C Marbury, Anne Flint, Jacob Bonde Jacobsen et al. · Clinical Pharmacokinetics Open access 27 Mar 2017 128
23 Pharmacokinetics of repaglinide in subjects with renal impairment Thomas C Marbury · Clinical Pharmacology & Therapeutics 2000 116
24 Cortical Suspensory Button Versus Aperture Interference Screw Fixation for Knee Anterior Cruciate Ligament Soft‐Tissue Allograft: A Prospective, Randomized Controlled Trial James H. Lubowitz, Randy Schwartzberg, Pat Smith · Arthroscopy The Journal of Arthroscopic and Related Surgery 21 Apr 2015 100
25 Efficacy and safety of indomethacin versus ritodrine in the management of preterm labor; A randomized study Morales Wj, S. R. Smith, Angel Jl et al. · International Journal of Gynecology & Obstetrics Apr 1990 95
26 Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine Richard Neil Greenberg, Thomas C Marbury, Ginamarie Foglia et al. · Vaccine 2 Feb 2012 93
27 An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan Suzanne Oparil, Robert M. Guthrie, Andrew J. Lewin et al. · Clinical Therapeutics May 1998 91
28 When nurse emotional intelligence matters: How transformational leadership influences intent to stay Lin Wang, Hong Tao, Barbara J. Bowers et al. · Journal of Nursing Management Open access 22 Apr 2018 88
29 Effects and Tolerability of Irbesartan Versus Enalapril in Patients With Severe Hypertension fn1fn1This study was supported by a grant from Bristol-Myers Squibb, Princeton, New Jersey. Pierre M. Larochelle, John M. Flack, Thomas C Marbury et al. · The American Journal of Cardiology Dec 1997 85
30 A novel, cell culture-derived smallpox vaccine in vaccinia-naïve adults Andrew W. Artenstein, Casey Johnson, Thomas C Marbury et al. · Vaccine 29 Jan 2005 84
31 Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily Robert Z. Harris, Desmond Padhi, Thomas C Marbury et al. · American Journal of Kidney Diseases Dec 2004 83
32 A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects Richard Neil Greenberg, Christine Mhorag Hay, Jack T. Stapleton et al. · PLoS ONE Open access 21 Jun 2016 82
33 Studies of the mechanism of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema: The effect of an ACE inhibitor on cutaneous responses to bradykinin, codeine, and histamine Michael W. Anderson, Richard D. deShazo · Journal of Allergy and Clinical Immunology Open access May 1990 81
34 Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension Steven G. Chrysant, Thomas C Marbury, Thomas D. Robinson · Journal of Human Hypertension 23 May 2003 80
35 The comprehensive anatomical spinal osteotomy and anterior column realignment classification Juan S. Uribe, Frank J. Schwab, Gregory M. Mundis et al. · Journal of Neurosurgery Spine Open access 24 Aug 2018 79
36 Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease Matthew J. Sheetz, Philip Barrington, Sophie Callies et al. · British Journal of Clinical Pharmacology Open access 25 Jan 2019 78
37 Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms LesterI. Harrison, ShariL. Skinner, ThomasC. Marbury et al. · Archives of Dermatological Research 8 Apr 2004 77
38 Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment Thomas C Marbury, James A. Dowell, Elyse Seltzer et al. · The Journal of Clinical Pharmacology 25 Mar 2009 76
39 Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function Reza Khosravan, Melvin Toh, May Garrett et al. · The Journal of Clinical Pharmacology 25 Sep 2009 76
40 Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy Eric Lawitz, Eliot W. Godofsky, Regine Rouzier et al. · Antiviral Research 20 Jan 2011 74
41 Gross and Pathologic Analysis of Long-Term Silicone Implants Inserted into the Human Body for Augmentation Rhinoplasty: 221 Revision Cases Dong Hak Jung, Bum Ryul Kim, Ji Yoon Choi et al. · Plastic & Reconstructive Surgery Dec 2007 74
42 Single‐Dose Pharmacokinetics and Safety of Pegylated Interferon‐α2b in Patients with Chronic Renal Dysfunction Samir Kumar Gupta, Amy L. Pittenger, Suzanne K. Swan et al. · The Journal of Clinical Pharmacology Oct 2002 72
43 Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim™, compared to AndroGel® Thomas C Marbury, E. Hamill, Romeo T. Bachand et al. · Biopharmaceutics & Drug Disposition 19 Feb 2003 71
44 GS‐9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double‐blind, dose‐ranging phase 1 study Maribel Rodriguez‐Torres, S. Glass, John M. Hill et al. · Journal of Viral Hepatitis Open access 9 Mar 2016 65
45 Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment Shawn D. Flanagan, Sonia L. Minassian, Denise Morris et al. · Antimicrobial Agents and Chemotherapy Open access 19 Aug 2014 63
46 A phase 1, randomized, dose‐ranging study of GS ‐5816, a once‐daily NS 5A inhibitor, in patients with genotype 1–4 hepatitis C virus Eric Lawitz, Bradley Freilich, John O. Link et al. · Journal of Viral Hepatitis Open access 16 Jul 2015 58
47 Effect of N-acetyl cysteine coated CdS:Mn/ZnS quantum dots on seed germination and seedling growth of snow pea (Pisum sativum L.): imaging and spectroscopic studies Smruti Das, Brandon P. Wolfson, Laurène Tétard et al. · Environmental Science Nano Open access 2015 58
48 A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment Daniel A. Tatosian et al. · Clinical Pharmacology & Therapeutics 24 Jul 2020 57
49 Local-gated single-walled carbon nanotube field effect transistors assembled by AC dielectrophoresis Paul Stokes, Saiful I Khondaker · Nanotechnology Open access 25 Mar 2008 57
50 Safety and Pharmacokinetics of the Antiorthopoxvirus Compound ST-246 following Repeat Oral Dosing in Healthy Adult Subjects Robert Anthony Jordan, Jarasvech Chinsangaram, Tové C. Bolken et al. · Antimicrobial Agents and Chemotherapy Open access 12 Apr 2010 56

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.